NBIX

Over the past six months, Neurocrine Biosciences' stock price has fluctuated due to positive clinical data, financial results, and some safety concerns. In August 2026, Phase 4 KINECT-PRO data for INGREZZA showed improved patient quality of life. In July 2026, the company initiated a Phase 2 study of Crinecerfont in pediatric patients and reported strong second-quarter 2026 financial results, with Ingrezza sales growing 15% and Crenessity sales exceeding estimates, leading to raised full-year Ingrezza guidance. In August 2026, a Phase 1 clinical study for NBIP-'1968 was initiated. In September 2026, the stock declined due to reports of patient deaths potentially linked to its Vykat drug, raising safety concerns, though it later showed some resilience. As of September 23, 2026, NBIX stock fluctuated between $138.00 and $143.00, with a 52-week range of $122.14 to $186.12, experiencing a decrease of 7.11% over the last month and 9.22% over the previous week.